In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ReNeuron Group plc

http://www.reneuron.com/

Latest From ReNeuron Group plc

Deal Watch: J&J Begins 2022 With Trio Of Technology Alliances

Heading into the J.P. Morgan Healthcare conference, pharmas have been focusing on discovery alliances. J&J’s deals look into novel tissue-targeted drugs, ionic liquid delivery technology and cancer vaccine R&D. Lilly teams with Entos on novel methods for delivering neurology drugs.

Deal Watch Business Strategies

Deal Watch: Roche, Pfizer, GSK Close Out 2021 With Licensing Transactions

Ahead of the usual flurry of deal-making in January, Roche gets retinal cell therapy candidate from Lineage Cell Therapeutics, Pfizer subsidiary Amplyx licenses antiviral candidate to Vera, and GSK expands neurology tie-up with Ligand.

Deal Watch Business Strategies

England’s NICE Okays First Ever Peanut Allergy Treatment Palforzia

Aimmune Therapeutics secures agreement with NHS for “step change” in treating peanut allergy.

Europe United Kingdom

Coronavirus Update: AstraZeneca Makes Case For Vaxzevria Booster Against Omicron

Also, AstraZeneca presents more promising data for its COVID-19 antibody cocktail Evusheld and Novavax says its vaccine is able to neutralize the Omicron variant. 

Coronavirus COVID-19 Vaccines
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Nanotechnology, Chips, etc.
UsernamePublicRestriction

Register